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SUMMARY
Hepatitis C virus (HCV) is an important factor contributing to morbidity and mortality in patients co-infected with HIV and
HCV. In addition, liver biopsy is an important tool in the clinical management of these patients. Although liver biopsy is controversial,
it is recommended for all patients. Data regarding the clinical and histological characteristics of these patients are scarce not only
in Brazil but in Latin America as a whole. With the goal of better understanding these characteristics and the benefit of liver biopsy
indications in this disease setting, data collected from 234 patients followed from 1996 to 2004 at Casa da AIDS, São Paulo, were
analyzed. The following variables were extracted from the patients’ medical files at the time of liver biopsy: sex, age, hepatitis C
infection risk factors, hepatitis C infection duration, ALT levels, CD4+ T cell counts, history of alcohol abuse, history of antiretroviral
therapy, HCV genotype, and liver histological alterations. Conclusions: 1 - Hepatitis C virus 1 and 3 were the most frequently
identified genotypes and were diagnosed in 72% and 25.5% of cases respectively; 2 - Structural liver alterations were found to be
mild or absent in 48.2% (113/234) of the analyzed patients; 3 - Fifty-three patients (23%) had normal ALT levels and 4 - Significant
liver architectural changes (F2-F3) were evident in 22.5% of the patients with normal ALT levels.
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INTRODUCTION
As hepatitis C virus (HCV) and HIV share the same mechanisms
of infection, co-infection with these two viruses is very common and
occurs in at least 30% of HIV-infected patients. Hepatitis C has become
an important cause of morbidity and mortality among HIV patients1,17,23.
Therefore, the adequate management of HCV is now a subject of great
interest.
The role of liver biopsies in patient care is controversial26,27. Some
clinicians believe that the indication for liver biopsy is optional and
only necessary if specific HCV treatment is recommended. Other
clinicians dispute this position and argue that the biopsy procedure
might offer essential information for patient care.
It is also uncertain whether liver biopsy should be recommended
for HCV patients with a normal alanine aminotransferase (ALT) level26.
In Brazil, the prevalence of HCV infection among HIV infected
patients ranges from 17% to 53% depending on the study8,12,15,18,25.
Nonetheless, clinical and histological data on these patient
characteristics are limited.
This study was conceived with the intention to further the
knowledge of the clinical and histological aspects of hepatitis C virus
infection among HIV-infected patients.
PATIENTS AND METHODS
The present study included HIV-HCV co-infected patients under
medical care at Casa da AIDS, Hospital das Clinicas, University of
São Paulo Medical School. Casa da AIDS (AIDS’ Home) is a specialized
medical center devoted to the care of HIV-infected patients. It is
currently in charge of approximately 3,500 patients.
In 1996, a group specifically directed towards the medical attention
of HIV, HCV and/or HBV-co-infected patients was created at Casa da
AIDS. All patients under this group’s medical care from October 1996
to October 2004 were initially included in this study.
For HIV diagnosis, an enzyme immunosorbent assay (EIA) was
used followed by confirmation with commercial enzyme-linked
immunosorbent assays (Organon Technika, Tournault, Belgium; and
Embrabio, São Paulo, Brazil). Specimens that tested positive after EIA
and those with discordant or indeterminate results were confirmed by
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Western blotting analysis. EIA was also used for hepatitis B diagnosis,
specifically to determine HbsAg positivity, HBs antibodies, HBc total
antibodies, HBeAg, and HBe antibodies. Third-generation EIAs for
HCV antibodies were used in hepatitis C analysis. To test HCV RNA
presence, nested polymerase chain reactions were employed. The
genotyping was performed by a reverse hybridization assay, the Line
Probe Assay (INNO-LiPA HCV / VERSANTTM HCV Genotype Assay
- Bayer Corporation, Tarrytown, NY, USA), based on hybridization of
labeled PCR amplification products to specific probes directed against
the variable regions of the 5’ NCR of the genotypes 1, 2, 3, 4, 5, 6 and
1a, 1b, 2a/2c, 2b, 5a and 6a subtypes. All patients were confirmed to
have HIV and HCV infection. Every patient who underwent liver biopsy
had reagent RNA testing for HCV using the PCR technique.
During the period mentioned above, 600 patients were followed.
For the purpose of the study’s analysis, patients whose clinical and
histological data were available were identified. Those who had not
undergone a liver biopsy were not included. The same option was
applied to those diagnosed with hepatocellular carcinoma, those who
were AgHBs positive, individuals with a history of interferon or ribavirin
use before the biopsy and cases in which medical information was
incomplete.
Liver biopsy recommendation for the study patients was based on
the significance of liver biopsy in evaluating HCV-related hepatopathy
and for the assessment of specific treatment necessity. Even though
there was no treatment indication at the time of biopsy for 49 patients,
the procedure was carried out according to the judgement of the
attending physician, as the CD4+ T cells counts were less than 200.
Patients with normal liver enzyme levels and CD4+ T cell counts higher
than 200, also underwent biopsy, following a clinical protocol approved
by the institution’s Ethics Committee.
Histological analysis was carried out by Hospital das Clinicas
Pathology Department using criteria validated by the Brazilian
Hepatology and Pathology Society6. Liver aggression staging followed
a necroinflamatory activity score ranging from 0 to 4 and a liver
architectural change score also ranging from 0 to 4.
Analyzed factors: Medical records were reviewed for this study
by three staff physicians. Patients from whom the following information
was retrieved were included in the analysis: demographic characteristics
(age; sex), HIV and HCV infection risk factors, alcohol abuse history,
antiretroviral therapy history, CD4+ T cell counts and ALT levels at the
time of biopsy, hepatitis C infection span (in cases of viral parenteral
transmission) and HCV genotype. Variable response rates were greater
than 90% throughout the duration of the medical record research.
Information regarding alcohol abuse was included if ingestion of
quantities ≥ 50 g of alcohol per day for ≥ 06 months occurred at any
time prior to liver biopsy. Information on antiretroviral drug therapy
antecedent was considered positive when therapy was reported by the
patients as having happened at any time before liver biopsy for at least
six consecutive months. CD4+ T cell count levels contemporary to the
biopsy were registered. Values from six months prior to six months
after the procedure were accepted. If more than one value was found,
the arithmetic medium of the results was taken into consideration.
ALT levels from the same period were also found and registered. If
more than one value was identified, the arithmetic medium was taken
into consideration.
We also included patients with persistently normal ALT levels (i.e.,
subjects with at least three consecutive normal ALT determinations
during a pre-biopsy follow-up of 12 months).
This study was carried out with the approval of the Ethics and
Research Committee of Hospital das Clinicas, University of São Paulo
Medical School.
RESULTS
Six hundred HIV-HCV-co-infected patients followed by the viral
hepatitis group at Casa da AIDS were submitted for analysis. Three
hundred sixty-five patients were excluded from the study for the
following reasons: absence of liver biopsy (287), hepatocellular
carcinoma diagnosis (2), positive serology for AgHBs (26) and
incomplete clinical data (50).
Two hundred thirty-four patients (234) were thus further analyzed
in this study having complete clinical data (at least six of the eight
analyzed factors) and liver biopsy information. Table 1 summarizes
the clinical and demographic characteristics, while Tables 2, 3 and 4
show histological findings.
Study Population: Most patients were male (74.3%) and former
IDUs (50.8%). Up to 62.8% of patients admitted prior high alcohol
intake. The median age at the time of liver biopsy was 39 years
(39 ± 7).
Table 1
Clinical data at the time of biopsy
Age, years, Mean, SD 39 ± 7
Sex, male 174 (74.3%)
CD4+ T cell count, cells/mm3 Median ± SD 389 ± 241
ARV therapy history - Yes 195 (83.3%)
ARV therapy history - No 20
ARV therapy history - Unavailable 19
Alcohol consumption history - Yes 147 (62.8%)
Alcohol consumption history - No 68
Alcohol consumption history - Unavailable 19
HCV infection risk factors
Endovenous drug use 119 (50.8%)
Blood transfusion  04
Percutaneous accident  02
Other, non-parenteral  63
Unavailable  20
HCV genotype
Genotype 1 121 (72%)
Genotype 2 04 (2.3%)
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Most patients (83%) were taking HAART. The median CD4+ T
cell count at the time of liver biopsy was 389 cells/mm3 (SD ± 241),
and 49 patients had a CD4+ T cell count of < 200 cells/mm3.
Seventy-six per cent of patients (181/234) had abnormal ALT values.
ALT levels were on average two and a half times superior to the limits
of normality.
The distribution of genotypes was as follows: 121 (72%) of patients
were infected with genotype 1, 4 (2.3%) with genotype 2, 43 (25.5%)
with genotype 3. None of the patients had mixed genotypes (Table 1).
Liver Biopsy: The distribution of patients according to liver fibrosis
was as follows: F0-F1 in 82 patients (35%), F2 in 51 patients (21.7%),
F3 in 39 patients (16.6%) and F4 in 20 patients (8.5%).
Reactional liver was observed in 31 patients (13.2%) and other
histopathological diagnoses were observed in 11 patients (4.7%)
(Table 2).
Among patients with normal ALT levels, the distribution of patients
according to liver fibrosis was as follows: F0 in seven patients (13.2%),
F1 in 20 patients (37.7%), F2 in nine patients (16.9%), and F3 in three
patients (5.6%). Reactional liver was observed in 14 patients (26.4%)
(Table 3).
Liver biopsy led to the diagnosis of other hepatic diseases in 11
cases (11/234) (Table 4). Five of the hepatic disease cases were affected
by liver steatosis, five by liver mycobacteriosis, and one by liver
histoplasmosis.
DISCUSSION
The results of this study demonstrate that liver biopsy was able to
not only stage chronic hepatitis caused by HCV but also to diagnose
other diseases in 4.7% of the analyzed cases (Table 2/Table 4). This
study also demonstrates that even patients with normal hepatic enzyme
levels might have advanced liver disease (Table 3).
The medical literature has not reached a consensus on whether
liver biopsy should be recommended for every patient, especially when
the HIV-HCV-co-infected population is in question26,27. In our
experience, liver biopsy is recommended as a routine for every patient,
including those who have normal hepatic enzyme levels. In Brazil,
there are no data available concerning histological characteristics of
these patients and evaluation of the actual necessity of biopsy.
Our data demonstrate that 113 (48.2%) of the analyzed patients
had absent or minimal hepatic disease (F0-F1) (Table 2). These numbers
convey a higher percentage of patients with mild liver disease compared
to those found in similar studies. Such studies report from 35 to 43%
Table 2
Liver histological alterations for 234 HIV-hepatitis C virus co-infected patients
Number of biopsies 234
Hepatitis Hepatitis
fibrosis stage activity grade
F0-F1 82 (35%) A0-A1 46 (19.6%)
F2 51 (21.7%) A2 66 (28.2%)
F3 39 (16.6%) A3 65 (27.7%)
F4 20 (8.5%) A4 15 (6.4%)
Reactional liver* 31 (13.2%)
Other diagnosis 11 (4.7%)
*Reactional liver: borderline histological pattern set between normality and
chronic hepatitis, and characterized by a staging score of 0 or 1, and a periportal
activity score of 0.
Table 3
 Liver histological changes among patients with normal ALT levels
Number of biopsies  53
Hepatitis Hepatitis
fibrosis stage activity grade
F0 07 (13.2%) A0 02 (3.7%)
F1 20 (37.7%) A1 12 (22.6%)
F2 09 (16.9%) A2 17 (32%)
F3 03 (5.6%) A3 08 (15%)
F4 ZERO A4 ZERO
Reactional liver 14 (26.4%)
Other diagnosis ZERO
Table 4
Liver histological changes grouped according to CD4+ T cell levels
Number of biopsies* 11 38 56 56 54
CD4 < 100 100-200 201-349 350-500 > 500
F3-F4 2 (18%) 11 (28.9%) 13 (23.2%) 17 (30.3%) 13 (24%)
Reactional liver 8 11 4 5
Other diagnosis
Steatosis 1 2 1 1
Mycobacteriosis 3 2
Histoplasmosis 1
*Number of biopsies for which CD4 cell count levels were known: Total = 215
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of mild disease cases among biopsied patients9,10,14,20. However, the
present study included patients with normal hepatic enzyme levels,
which sets it apart from other studies and might account for the
differences in results.
In our analysis, 25% of the patients suffered from severe liver
aggression (F3-F4) (Table 2).
Cirrhosis is the final stage of liver fibrosis progression. Evolution
from infection to cirrhosis is faster in HIV-HCV-co-infected patients
compared to patients who are only infected with HCV11,26. Nonetheless,
there are great variations in the length of time necessary for such
progression and many contributing factors. Some of these factors are
well known: time of infection, age, male gender, alcohol abuse, HIV
co-infection, and low CD4+ T cell counts. Metabolic conditions such
as liver steatosis, excess weight and diabetes also appear to contribute
to liver fibrosis progression.
The association between these variables and advanced fibrosis was
not analyzed in this study. However, it was observed that there was not
a significant difference in the incidence of these factors when patients
were grouped according to their CD4+ T cell count (Table 4).
Concerning the analysis of ALT levels at the time of biopsy, it is
relevant to note that most patients (76.1%) (Table 1) had increased
enzyme values that were on average two and a half times higher than
the limits of normality.
Regarding the histological findings among patients with normal
ALT levels, it was observed that significant liver architectural changes
(F2-F3) were evident in 22.5% of the patients with normal ALT levels.
Among the patients with significant liver architectural changes three
patients (5.6%) had advanced fibrosis (F3). It was also observed that
eight patients (15%) had advanced necroinflammatory liver aggression
(A3) (Table 3).
We believe that liver biopsy should be recommended for HIV-HCV-
co-infected patients regardless of whether hepatic enzymes are altered.
Our results demonstrating that severe liver disease occurs even among
patients with normal alanine aminotransferase levels are supported by
other recent work with similar conclusions5,7,28.
Liver biopsy led to the diagnosis of other hepatic diseases in 11
cases (11/234) (Table 4). Five of these cases were affected by liver
steatosis, five by liver mycobacteriosis, and one by liver histoplasmosis.
In the aforementioned cases, liver biopsy served as a diagnosis tool,
allowing for the detection of unknown conditions. It should be pointed
out that mycobacteriosis and histoplasmosis were diagnosed among
patients with severe immunological compromise and CD4+T cell counts
lower than 200 (Table 4). These liver biopsy recommendations were
based on the fact that in the course of diagnostic investigation elevated
cellular and canalicular enzyme levels (ALT, AST, GGT and alkaline
phosphatase) were observed in the presence of serum HCV-RNA.
Of the identified HCV genotypes, genotype 1 was the most
frequently identified, corresponding to 72% (121) of the cases.
Genotype 3 was found in 43 cases (25.5%) and genotype 2 in four
cases (2.3%)(Table 1). Similar results have been reported by other
studies that evaluated the same parameters among coinfected
patients21,22,24. Our findings are also consistent with those described in
a study evaluating HCV genotypic distribution among mono-infected
patients in Brazil2,3,4,16.
Intravenous drug use was the most frequently reported HCV
infection risk factor, which is supported by other studies on this topic13.
It is our belief that our study strengthens the case for liver biopsy
as an important tool in the management and treatment recommendation
for hepatitis C in our setting.
Almost half of the patients (48.2%) had mild liver disease at biopsy.
In our opinion, treatment recommendation for these patients should
be individualized with the objective of reducing iatrogenic
complications and treatment costs.
Hepatitis C treatment is mandatory for those who have clear clinical
indications and treatment introduction at the appropriate time
undoubtedly prevents complications such as liver failure, cirrhosis and
hepatocellular carcinoma. Nevertheless, HCV treatment also involves
the risk of severe adverse effects, potential drug interactions and a
much higher financial burden. As mentioned before, HCV treatment
recommendations should be decided on a case-by-case basis to improve
the chances of success.
In addition to what has been described here, liver biopsy might
serve as a diagnostic tool for other diseases that affect HIV-HCV co-
infected patients. It might also provide an important accessory for
clinical monitoring during future treatments, such as during chronic
hepatitis re-treatment.
RESUMO
Características clínicas e histológicas de pacientes co-infectados
pelo HIV e vírus da hepatite C no Brasil: estudo de uma série de
casos
A infecção causada pelo vírus da hepatite C (VHC) constitui
importante causa de morbidade e mortalidade entre pacientes co-
infectados pelo HIV e VHC. A indicação da realização de biópsia
hepática nesses pacientes é controversa, podendo constituir importante
ferramenta no manejo clínico desses pacientes. São escassos os dados
relativos às características clínicas e histopatológicas dos pacientes
co-infectados no Brasil e em toda a América Latina. Com o objetivo
de analisar as características clínicas e histopatológicas em co-
infectados e avaliar os benefícios da realização de biópsia hepática
nesse grupo de pacientes, analisamos dados relativos a 234 pacientes
acompanhados na Casa da AIDS, São Paulo, de 1996 a 2004. A partir
de informações obtidas em prontuários, foram analisadas as seguintes
variáveis relativas aos pacientes, coletadas à época da realização da
biópsia hepática: gênero, idade, fatores de risco para a transmissão da
hepatite C, tempo estimado de infecção pelo VHC, níveis séricos de
ALT, contagem de células CD4, antecedentes relativos ao uso de álcool,
antecedente de uso de terapia antiretroviral, genótipo de VHC e
alterações histológicas obtidas através da biópsia hepática. Conclusões:
1- Os genótipos 1 e 3 foram os mais freqüentes nessa população,
representando cerca de 72% e 25,5% dos casos analisados
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respectivamente; 2- Alterações estruturais hepáticas leves ou ausentes
foram observadas em 48,2% dos pacientes (113/234); 3- Cinqüenta e
três pacientes (23%) apresentaram níveis de ALT persistentemente
normais; 4- Alterações estruturais significativas (F2-F3) foram
observadas em 22,5% entre pacientes com níveis de ALT
persistentemente dentro da normalidade.
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